Pelago Bioscience Acquires RG Discovery
June 15, 2026
Pelago Bioscience, a cell-based target engagement contract research organization (CRO), has acquired RG Discovery to create an integrated drug discovery platform spanning biology and medicinal chemistry. The combination is intended to support customers across the full DMTA (design-make-test-analyze) cycle with a single specialist partner, reducing workflow handoffs from hit identification through lead optimization.
- Buyers
- Pelago Bioscience
- Targets
- RG Discovery
- Industry
- Healthcare Services
- Location
- Sweden
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.